drugset
drugset / Trial / NCT04510298

A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

NCT04510298 ↗

Phase 1 Completed 27 enrolled Sirtsei Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 1B clinical study evaluating the safety and exploring the effectiveness of SP-624 as compared to placebo in the treatment of adults with schizophrenia experiencing acute psychosis.

Timeline

Start
2020-10-15
Primary completion
2021-04-15
Completion
2021-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject SP-624 Unknown 20 mg Oral

Indications

schizophrenia